Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Laurence Albiges; Tom Powles; Michael Staehler; Karim Bensalah; Rachel H. Giles; Milan Hora; Markus A. Kuczyk; Thomas B. Lam; Börje Ljungberg; Lorenzo Marconi; Axel S. Merseburger; Alessandro Volpe; Yasmin Abu-Ghanem; Saeed Dabestani; Sergio Fernández-Pello; Fabian Hofmann; Teele Kuusk; Rana Tahbaz; Axel Bex

doi:10.1016/j.eururo.2019.05.022

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Laurence Albiges, Tom Powles, Michael Staehler, Karim Bensalah, Rachel H. Giles, Milan Hora, Markus A. Kuczyk, Thomas B. Lam, Börje Ljungberg, Lorenzo Marconi, Axel S. Merseburger, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernández-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Axel Bex^*

^*Corresponding author for this work

Clinic of Urology

183 Citations (Scopus)

Abstract

Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

Original language	English
Journal	European Urology
Volume	76
Issue number	2
Pages (from-to)	151-156
Number of pages	6
ISSN	0302-2838
DOIs	https://doi.org/10.1016/j.eururo.2019.05.022
Publication status	Published - 08.2019

Funding

Financial disclosures: Axel Bex certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Professor Dr. Laurence Albiges has received consulting/advisory fees from BMS, Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer, and Cerulean; and research funding from Pfizer and Novartis. Professor Dr. Tom Powles is a company consultant for Novartis, Pfizer, and GlaxoSmithKline; has received company speaker honoraria from Novartis, Pfizer, GlaxoSmithKline, and Genentech; has participated in trials for GlaxoSmithKline, Pfizer, BMS, Genentech, and Genetech; and has received grants/research support from GlaxoSmithKline, Pfizer, and Novartis. Professor Dr. Michael Staehler is a company consultant for Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, and Bayer; has received company speaker honoraria from Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, Bayer, and Aveo; has participated in trials for Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, Aveo, Wilex, and Immatics; has received fellowships and travel grants from Pfizer, Novartis, GlaxoSmithKline, Roche, and Bayer; has received grants/research support from Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, and Aveo; and, in addition, took part in the S-TRAC trial as an investigator and is an author of the S-TRAC publication. Professor Dr. Karim Bensalah has received grants/research support from Pfizer, and honoraria or consultation fees from Intuitive Surgical. Professor Dr. Milan Hora has received company speaker honoraria from Covidien, Olympus, Janssen, and Astellas; has participated in trials for Janssen; and has received grants/research support from Ipsen. Professor Dr. Markus A. Kuczyk is a stock shareholder of Bayer Healthcare, Astellas, Storz, Pfizer, Wyeth, and Novartis; is a company consultant for Karl Storz, Coloplast, AstraZeneca, Astellas, Storz, and Hexal; has received company speaker honoraria from Pfizer, Astellas, Bayer, GlaxoSmithKline, Pierre Fabre, Janssen Cilag, and Hexal; has participated in trials for the ProtecT Study, Millenium Study C21004, Millenium Study C21005, Astellas, Ipsen, and Janssen; and has received grants/research support from Wyeth and Pfizer. Dr. Thomas B. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GlaxoSmithKline, Astellas, and Ipsen. Professor Dr. Börje Ljungberg has received company speaker honoraria from GlaxoSmithKline, Roche, Pfizer, and Novartis; has participated in trials for GlaxoSmithKline, Medivation, Pfizer, and Janssen R&D; and has been on advisory boards for Pfizer and GlaxoSmithKline. Professor Dr. Axel S. Merseburger is a company consultant for Ipsen Pharma, Bayer, Astellas, Janssen Cilag, Novartis, and Pfizer; has received company speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for AstraZeneca, Bayer, Pfizer, TEVA, Novartis, and Astellas; has received grants/research support from Wyeth; and has participated in a company-sponsored speakers bureau for TEVA, Janssen, Pfizer, Astellas, Ferring, and Novartis. Professor Dr. Axel Bex has received company speaker honoraria from Pfizer; has participated in trials for Pfizer Europe; has participated in advisory boards for GlaxoSmithKline and Novartis; is a company consultant for Pfizer and Novartis; and has received grants/research support from Pfizer. Professor Dr. Rachel H. Giles, Professor Dr. Alessandro Volpe, Dr. Saeed Dabestani, Dr. Fabian Hofmann, Dr. Lorenzo Marconi, Dr. Sergio Fernández-Pello, Dr. Rana Tahbaz, and Dr. Yasmin Abu-Ghanem have nothing to disclose.

DFG Research Classification Scheme

2.22-23 Reproductive Medicine, Urology

Coronavirus related work

Research on SARS-CoV-2 / COVID-19

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2019.05.022

Cite this

Albiges, L., Powles, T., Staehler, M., Bensalah, K., Giles, R. H., Hora, M., Kuczyk, M. A., Lam, T. B., Ljungberg, B., Marconi, L., Merseburger, A. S., Volpe, A., Abu-Ghanem, Y., Dabestani, S., Fernández-Pello, S., Hofmann, F., Kuusk, T., Tahbaz, R., & Bex, A. (2019). Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. European Urology, 76(2), 151-156. https://doi.org/10.1016/j.eururo.2019.05.022

@article{ae1a95c999ab4f3cb68da3a608154014,

title = "Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma",

abstract = "Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment na{\"i}ve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.",

author = "Laurence Albiges and Tom Powles and Michael Staehler and Karim Bensalah and Giles, \{Rachel H.\} and Milan Hora and Kuczyk, \{Markus A.\} and Lam, \{Thomas B.\} and B{\"o}rje Ljungberg and Lorenzo Marconi and Merseburger, \{Axel S.\} and Alessandro Volpe and Yasmin Abu-Ghanem and Saeed Dabestani and Sergio Fern{\'a}ndez-Pello and Fabian Hofmann and Teele Kuusk and Rana Tahbaz and Axel Bex",

note = "Funding Information: Financial disclosures: Axel Bex certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Professor Dr. Laurence Albiges has received consulting/advisory fees from BMS, Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer, and Cerulean; and research funding from Pfizer and Novartis. Professor Dr. Tom Powles is a company consultant for Novartis, Pfizer, and GlaxoSmithKline; has received company speaker honoraria from Novartis, Pfizer, GlaxoSmithKline, and Genentech; has participated in trials for GlaxoSmithKline, Pfizer, BMS, Genentech, and Genetech; and has received grants/research support from GlaxoSmithKline, Pfizer, and Novartis. Professor Dr. Michael Staehler is a company consultant for Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, and Bayer; has received company speaker honoraria from Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, Bayer, and Aveo; has participated in trials for Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, Aveo, Wilex, and Immatics; has received fellowships and travel grants from Pfizer, Novartis, GlaxoSmithKline, Roche, and Bayer; has received grants/research support from Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, and Aveo; and, in addition, took part in the S-TRAC trial as an investigator and is an author of the S-TRAC publication. Professor Dr. Karim Bensalah has received grants/research support from Pfizer, and honoraria or consultation fees from Intuitive Surgical. Professor Dr. Milan Hora has received company speaker honoraria from Covidien, Olympus, Janssen, and Astellas; has participated in trials for Janssen; and has received grants/research support from Ipsen. Professor Dr. Markus A. Kuczyk is a stock shareholder of Bayer Healthcare, Astellas, Storz, Pfizer, Wyeth, and Novartis; is a company consultant for Karl Storz, Coloplast, AstraZeneca, Astellas, Storz, and Hexal; has received company speaker honoraria from Pfizer, Astellas, Bayer, GlaxoSmithKline, Pierre Fabre, Janssen Cilag, and Hexal; has participated in trials for the ProtecT Study, Millenium Study C21004, Millenium Study C21005, Astellas, Ipsen, and Janssen; and has received grants/research support from Wyeth and Pfizer. Dr. Thomas B. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GlaxoSmithKline, Astellas, and Ipsen. Professor Dr. B{\"o}rje Ljungberg has received company speaker honoraria from GlaxoSmithKline, Roche, Pfizer, and Novartis; has participated in trials for GlaxoSmithKline, Medivation, Pfizer, and Janssen R\&D; and has been on advisory boards for Pfizer and GlaxoSmithKline. Professor Dr. Axel S. Merseburger is a company consultant for Ipsen Pharma, Bayer, Astellas, Janssen Cilag, Novartis, and Pfizer; has received company speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for AstraZeneca, Bayer, Pfizer, TEVA, Novartis, and Astellas; has received grants/research support from Wyeth; and has participated in a company-sponsored speakers bureau for TEVA, Janssen, Pfizer, Astellas, Ferring, and Novartis. Professor Dr. Axel Bex has received company speaker honoraria from Pfizer; has participated in trials for Pfizer Europe; has participated in advisory boards for GlaxoSmithKline and Novartis; is a company consultant for Pfizer and Novartis; and has received grants/research support from Pfizer. Professor Dr. Rachel H. Giles, Professor Dr. Alessandro Volpe, Dr. Saeed Dabestani, Dr. Fabian Hofmann, Dr. Lorenzo Marconi, Dr. Sergio Fern{\'a}ndez-Pello, Dr. Rana Tahbaz, and Dr. Yasmin Abu-Ghanem have nothing to disclose. Publisher Copyright: {\textcopyright} 2019 European Association of Urology Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = aug,

doi = "10.1016/j.eururo.2019.05.022",

language = "English",

volume = "76",

pages = "151--156",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

Albiges, L, Powles, T, Staehler, M, Bensalah, K, Giles, RH, Hora, M, Kuczyk, MA, Lam, TB, Ljungberg, B, Marconi, L, Merseburger, AS, Volpe, A, Abu-Ghanem, Y, Dabestani, S, Fernández-Pello, S, Hofmann, F, Kuusk, T, Tahbaz, R & Bex, A 2019, 'Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma', European Urology, vol. 76, no. 2, pp. 151-156. https://doi.org/10.1016/j.eururo.2019.05.022

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. / Albiges, Laurence; Powles, Tom; Staehler, Michael et al.
In: European Urology, Vol. 76, No. 2, 08.2019, p. 151-156.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

AU - Albiges, Laurence

AU - Powles, Tom

AU - Staehler, Michael

AU - Bensalah, Karim

AU - Giles, Rachel H.

AU - Hora, Milan

AU - Kuczyk, Markus A.

AU - Lam, Thomas B.

AU - Ljungberg, Börje

AU - Marconi, Lorenzo

AU - Merseburger, Axel S.

AU - Volpe, Alessandro

AU - Abu-Ghanem, Yasmin

AU - Dabestani, Saeed

AU - Fernández-Pello, Sergio

AU - Hofmann, Fabian

AU - Kuusk, Teele

AU - Tahbaz, Rana

AU - Bex, Axel

N1 - Funding Information: Financial disclosures: Axel Bex certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Professor Dr. Laurence Albiges has received consulting/advisory fees from BMS, Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer, and Cerulean; and research funding from Pfizer and Novartis. Professor Dr. Tom Powles is a company consultant for Novartis, Pfizer, and GlaxoSmithKline; has received company speaker honoraria from Novartis, Pfizer, GlaxoSmithKline, and Genentech; has participated in trials for GlaxoSmithKline, Pfizer, BMS, Genentech, and Genetech; and has received grants/research support from GlaxoSmithKline, Pfizer, and Novartis. Professor Dr. Michael Staehler is a company consultant for Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, and Bayer; has received company speaker honoraria from Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, Bayer, and Aveo; has participated in trials for Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, Aveo, Wilex, and Immatics; has received fellowships and travel grants from Pfizer, Novartis, GlaxoSmithKline, Roche, and Bayer; has received grants/research support from Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, and Aveo; and, in addition, took part in the S-TRAC trial as an investigator and is an author of the S-TRAC publication. Professor Dr. Karim Bensalah has received grants/research support from Pfizer, and honoraria or consultation fees from Intuitive Surgical. Professor Dr. Milan Hora has received company speaker honoraria from Covidien, Olympus, Janssen, and Astellas; has participated in trials for Janssen; and has received grants/research support from Ipsen. Professor Dr. Markus A. Kuczyk is a stock shareholder of Bayer Healthcare, Astellas, Storz, Pfizer, Wyeth, and Novartis; is a company consultant for Karl Storz, Coloplast, AstraZeneca, Astellas, Storz, and Hexal; has received company speaker honoraria from Pfizer, Astellas, Bayer, GlaxoSmithKline, Pierre Fabre, Janssen Cilag, and Hexal; has participated in trials for the ProtecT Study, Millenium Study C21004, Millenium Study C21005, Astellas, Ipsen, and Janssen; and has received grants/research support from Wyeth and Pfizer. Dr. Thomas B. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GlaxoSmithKline, Astellas, and Ipsen. Professor Dr. Börje Ljungberg has received company speaker honoraria from GlaxoSmithKline, Roche, Pfizer, and Novartis; has participated in trials for GlaxoSmithKline, Medivation, Pfizer, and Janssen R&D; and has been on advisory boards for Pfizer and GlaxoSmithKline. Professor Dr. Axel S. Merseburger is a company consultant for Ipsen Pharma, Bayer, Astellas, Janssen Cilag, Novartis, and Pfizer; has received company speaker honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP; has participated in trials for AstraZeneca, Bayer, Pfizer, TEVA, Novartis, and Astellas; has received grants/research support from Wyeth; and has participated in a company-sponsored speakers bureau for TEVA, Janssen, Pfizer, Astellas, Ferring, and Novartis. Professor Dr. Axel Bex has received company speaker honoraria from Pfizer; has participated in trials for Pfizer Europe; has participated in advisory boards for GlaxoSmithKline and Novartis; is a company consultant for Pfizer and Novartis; and has received grants/research support from Pfizer. Professor Dr. Rachel H. Giles, Professor Dr. Alessandro Volpe, Dr. Saeed Dabestani, Dr. Fabian Hofmann, Dr. Lorenzo Marconi, Dr. Sergio Fernández-Pello, Dr. Rana Tahbaz, and Dr. Yasmin Abu-Ghanem have nothing to disclose. Publisher Copyright: © 2019 European Association of Urology Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/8

Y1 - 2019/8

N2 - Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

AB - Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

UR - https://www.scopus.com/pages/publications/85066081578

U2 - 10.1016/j.eururo.2019.05.022

DO - 10.1016/j.eururo.2019.05.022

M3 - Journal articles

C2 - 31151678

AN - SCOPUS:85066081578

SN - 0302-2838

VL - 76

SP - 151

EP - 156

JO - European Urology

JF - European Urology

IS - 2

ER -

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Abstract

Funding

DFG Research Classification Scheme

Coronavirus related work

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this